How do hospital procurement teams evaluate suppliers in the Biosimilars Market?

Tenders weigh supply reliability, device usability and multi-year price stability more heavily than headline discount. Single-winner Nordic awards have cut prices sharply but concentrated national supply risk. Dual-sourcing clauses are now common. [12] Read More

What separates biosimilar development economics from small-molecule generics?

A biosimilar programme typically costs USD 100–250 million and runs about eight years, against under USD 5 million for a generic. That capital barrier keeps entrant counts per molecule in single digits. [7] Read More

Does interchangeability designation guarantee pharmacy substitution?

No. Substitution rules are set state by state in the US, and most require prescriber notification. Designation improves payer negotiating position more than it changes dispensed volume. [14] Read More

How is contract manufacturing capacity shaping the Biosimilars Market?

Dedicated CDMO capacity now exceeds two million litres globally, letting mid-tier developers skip capital builds entirely. Slot scarcity for high-titre mammalian lines remains the binding scheduling constraint through 2028. [11] Read More

Why do rebate structures slow adoption despite lower list prices?

Originators bundle rebates across product portfolios so that a lower-list biosimilar can cost formularies more in net terms. Several US payers have responded with mandatory-switch policies rather than renegotiating contracts. [9] Read More

Which emerging-economy regulators matter most for the Biosimilars Market?

China's NMPA, India's CDSCO and Brazil's ANVISA. All three now accept abbreviated comparative pathways aligned to WHO guidance, which reduces duplicate clinical work for exporters targeting multiple regions. [18] Read More

How much do cold-chain and device costs affect delivered price?

Cold-chain logistics and prefilled-device assembly can absorb 12–18% of total delivered cost. Device differentiation, rather than molecule quality, increasingly decides tender outcomes in the Biosimilars Market. [20] Read More

Biosimilars Market (2025 - 2035)

ID: MRFR/LS/0821-CR 209 Pages Nidhi Mandole Last Updated: September 15, 2026

Biosimilars Market Research Report: Size, Share, Trend Analysis By Drug Class (Monoclonal Antibodies (Adalimumab, Infliximab, Rituximab, Bevacizumab, Trastuzumab, Ustekinumab, Tocilizumab, Aflibercept, Dupilumab, Denosumab, Others), Insulin, Granulocyte Colony- stimulating Factor, Erythropoietin, Recombinant Human Growth Hormone, Etanercept, Follitropin, Teriparatide, Anticoagulants, Others), By Applications (Oncology (Breast Cancer, Lung Cancer, Prostate Cancer, Leukemia, Bladder Cancer, Colorectal Cancer, Others), Autoimmune Diseases, Infectious Diseases, Blood Disorders, Others), by Route of Administration (Subcutaneous and Intravenous), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, Specialty Pharmacies) and Region (North America, Europe, Asia-Pacific, South America, Middle East & Africa)) - Growth Outlook & Industry Forecast 2025 To 2035

Biosimilars Market

Market Size

Forecast Period2025-2035

CAGR (2025-2035)17.0%

2025 Market SizeUSD 40.2 Billion

2035 Market SizeUSD 193.2 Billion

Key Players

Sandoz

Celltrion

Samsung Bioepis

Amgen

Pfizer

Biocon Biologics

Trends

The Exclusivity Cliff Is Now the Sector's Clock
Reimbursement Turned From Obstacle to Accelerant
Regulators Removed the Redundant Clinical Step

Opportunities

The Checkpoint Inhibitor Cohort
Emerging-Market Regulatory Convergence
Device-Led Differentiation

Summary Table of Contents Segmentation Methodology Download PDF

1 Market Overview |
1. 1.1 Study Assumptions & Market Definition |
2. 1.2 Scope of the Study |
3. 1.3 Research Methodology
2 Market Summary & Key Report Takeaways |
1. 2.1 Takeaways by Product Class |
2. 2.2 Takeaways by Indication & End User |
3. 2.3 Takeaways by Geography
3 Global Market Size & Forecast (2021–2035) |
1. 3.1 Historical Market Size (2021–2024) |
2. 3.2 Base Year Estimate (2025) |
3. 3.3 Forecast Market Size (2026–2035) |
4. 3.4 Year-over-Year Growth Analysis
4 Market Dynamics — Drivers |
1. 4.1 Biologic Loss-of-Exclusivity Cliff |
2. 4.2 Payer Reimbursement Reform |
3. 4.3 Streamlined Comparability Pathways |
4. 4.4 Manufacturing Intensification Economics |
5. 4.5 National Tender Substitution Mandates |
6. 4.6 Emerging-Economy Regulatory Convergence
5 Market Dynamics — Restraints |
1. 5.1 Rebate Bundling by Originators |
2. 5.2 Development Cost & Timeline Intensity |
3. 5.3 Price Erosion and Entrant Returns |
4. 5.4 Patent Thickets & Litigation |
5. 5.5 Prescriber and Patient Switching Hesitancy
6 Market Opportunity Analysis |
1. 6.1 Checkpoint Inhibitor Expiry Cohort |
2. 6.2 Emerging-Market Regulatory Convergence |
3. 6.3 Device-Led Differentiation |
4. 6.4 Real-World Evidence Monetisation |
5. 6.5 Dedicated Contract Manufacturing |
6. 6.6 Industry Value Chain Analysis |
7. 6.7 Porter's Five Forces Analysis
7 Regional Analysis |
1. 7.1 North America | |
  1. 7.1.1 US | |
  2. 7.1.2 Canada | |
  3. 7.1.3 Mexico |
2. 7.2 Europe | |
  1. 7.2.1 Germany | |
  2. 7.2.2 UK | |
  3. 7.2.3 France | |
  4. 7.2.4 Italy | |
  5. 7.2.5 Spain | |
  6. 7.2.6 Nordic Countries | |
  7. 7.2.7 Russia | |
  8. 7.2.8 Rest of Europe |
3. 7.3 Asia-Pacific | |
  1. 7.3.1 China | |
  2. 7.3.2 India | |
  3. 7.3.3 Japan | |
  4. 7.3.4 South Korea | |
  5. 7.3.5 ASEAN | |
  6. 7.3.6 Rest of Asia-Pacific |
4. 7.4 South America | |
  1. 7.4.1 Brazil | |
  2. 7.4.2 Argentina | |
  3. 7.4.3 Rest of South America |
5. 7.5 Middle East & Africa | |
  1. 7.5.1 Saudi Arabia | |
  2. 7.5.2 UAE | |
  3. 7.5.3 South Africa | |
  4. 7.5.4 Egypt | |
  5. 7.5.5 Rest of Middle East & Africa
8 Future Outlook (2026–2035) |
1. 8.1 Analytics-Led Comparability |
2. 8.2 Platform Economics & Consolidation |
3. 8.3 Subcutaneous Conversion |
4. 8.4 Global Access Economics
9 Segmentation Analysis |
1. 9.1 By Product Class | |
  1. 9.1.1 Monoclonal Antibodies | |
  2. 9.1.2 Recombinant Hormones | |
  3. 9.1.3 Insulin & Insulin Analogues | |
  4. 9.1.4 Fusion Proteins & Anti-Inflammatory Agents | |
  5. 9.1.5 Others |
2. 9.2 By Indication | |
  1. 9.2.1 Blood Disorders | |
  2. 9.2.2 Autoimmune & Chronic Inflammatory | |
  3. 9.2.3 Oncology | |
  4. 9.2.4 Diabetes | |
  5. 9.2.5 Growth Deficiency & Others |
3. 9.3 By End User | |
  1. 9.3.1 Hospitals | |
  2. 9.3.2 Specialty Clinics | |
  3. 9.3.3 Retail & Homecare | |
  4. 9.3.4 Others |
4. 9.4 By Manufacturing Type | |
  1. 9.4.1 In-House | |
  2. 9.4.2 Contract Manufacturing |
5. 9.5 By Route of Administration | |
  1. 9.5.1 Intravenous | |
  2. 9.5.2 Subcutaneous
10 Competitive Landscape |
1. 10.1 Market Concentration Analysis (2026) |
2. 10.2 Competitive Benchmarking Matrix |
3. 10.3 Company Profiles | |
  1. 10.3.1 Sandoz | |
  2. 10.3.2 Celltrion | |
  3. 10.3.3 Samsung Bioepis | |
  4. 10.3.4 Amgen | |
  5. 10.3.5 Pfizer | |
  6. 10.3.6 Biocon Biologics | |
  7. 10.3.7 Viatris | |
  8. 10.3.8 Fresenius Kabi | |
  9. 10.3.9 Teva | |
  10. 10.3.10 Coherus BioSciences | |
  11. 10.3.11 Boehringer Ingelheim | |
  12. 10.3.12 Dr. Reddy's Laboratories
11 Recent Developments & News (2023–2025)
12 Report Scope & Methodology |
1. 12.1 Study Period & Base Year |
2. 12.2 Data Sources & Triangulation |
3. 12.3 Abbreviations
13 Detailed Sources & Citations
14 Frequently Asked Questions
15 LIST OF TABLES |
TABLE 1 Global Biosimilars Market Size & Forecast, by Revenue (USD Billion), 2021–2035 |
TABLE 2 Global Biosimilars Market — Year-over-Year Growth Analysis, 2021–2035 |
TABLE 3 Driver Impact Analysis Matrix, 2026–2035 |
TABLE 4 Restraint Impact Analysis Matrix, 2026–2035 |
TABLE 5 Global Market Size, by Product Class, 2021–2035 (USD Billion) |
TABLE 6 Global Market Size, by Indication, 2021–2035 (USD Billion) |
TABLE 7 Global Market Size, by End User, 2021–2035 (USD Billion) |
TABLE 8 Global Market Size, by Manufacturing Type, 2021–2035 (USD Billion) |
TABLE 9 Global Market Size, by Route of Administration, 2021–2035 (USD Billion) |
TABLE 10 Global Market Size, by Region, 2021–2035 (USD Billion) |
TABLE 11 North America Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 12 Europe Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 13 Asia-Pacific Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 14 South America Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 15 Middle East & Africa Market Size, by Country, 2021–2035 (USD Billion) |
TABLE 16 North America Market Size, by Product Class, 2021–2035 (USD Billion) |
TABLE 17 North America Market Size, by Indication, 2021–2035 (USD Billion) |
TABLE 18 Europe Market Size, by Product Class, 2021–2035 (USD Billion) |
TABLE 19 Europe Market Size, by Indication, 2021–2035 (USD Billion) |
TABLE 20 Asia-Pacific Market Size, by Product Class, 2021–2035 (USD Billion) |
TABLE 21 Asia-Pacific Market Size, by Indication, 2021–2035 (USD Billion) |
TABLE 22 South America Market Size, by Product Class, 2021–2035 (USD Billion) |
TABLE 23 Middle East & Africa Market Size, by Product Class, 2021–2035 (USD Billion) |
TABLE 24 Competitive Benchmarking Matrix, 2026 |
TABLE 25 Company Profiles — Key Players |
TABLE 26 Recent Developments & Strategic Announcements, 2023–2025 |
TABLE 27 Report Scope & Methodology Summary |
TABLE 28 Detailed Sources & Citations Index
16 LIST OF FIGURES |
FIGURE 1 Market Dynamics — Drivers, Restraints and Opportunities Snapshot |
FIGURE 2 Industry Value Chain Analysis |
FIGURE 3 Porter's Five Forces Analysis |
FIGURE 4 Global Market Size Trend, 2021–2035 (USD Billion) |
FIGURE 5 Year-over-Year Growth Trajectory, 2022–2035 |
FIGURE 6 Market Share by Product Class, 2025 vs 2035 |
FIGURE 7 Market Share by Indication, 2025 vs 2035 |
FIGURE 8 Market Share by End User, 2025 |
FIGURE 9 Market Share by Manufacturing Type, 2025 vs 2035 |
FIGURE 10 Market Share by Route of Administration, 2025 vs 2035 |
FIGURE 11 Regional Share Distribution, 2025 |
FIGURE 12 Regional Share Distribution, 2035 |
FIGURE 13 Regional CAGR Comparison, 2026–2035 |
FIGURE 14 Competitive Landscape — Estimated Share Bands, 2026 |
FIGURE 15 Loss-of-Exclusivity Calendar and Revenue at Risk, 2026–2032

Certified Researchers

Enquiry

Customize Report

Segmentation Quick Reference

Dimension	Sub-Segments	Dominant Segment	Fastest Growing Segment
By Product Class	Monoclonal Antibodies; Recombinant Hormones; Insulin & Insulin Analogues; Fusion Proteins & Anti-Inflammatory Agents; Others	Monoclonal Antibodies	Insulin & Insulin Analogues
By Indication	Blood Disorders; Autoimmune & Chronic Inflammatory; Oncology; Diabetes; Growth Deficiency & Others	Autoimmune & Chronic Inflammatory	Oncology
By End User	Hospitals; Specialty Clinics; Retail & Homecare; Others	Hospitals	Specialty Clinics
By Manufacturing Type	In-House; Contract Manufacturing	In-House	Contract Manufacturing
By Route of Administration	Intravenous; Sub-Cutaneous	Intravenous	Sub-Cutaneous
By Geography	North America; Europe; Asia-Pacific; South America; Middle East & Africa	Europe	Asia-Pacific

Market Segmentation Overview

By Product Class

Sub-Segment	Key Trend
Monoclonal Antibodies	Oncology and immunology expiries sustain the largest revenue pool
Recombinant Hormones	Fertility and growth indications drive steady replacement volumes.
Insulin & Insulin Analogues	Pharmacy-level substitution accelerates uptake post-reclassification
Fusion Proteins & Anti-Inflammatory Agents	Etanercept and aflibercept entries broaden the class.
Others	Enzymes and anticoagulants form a small but expanding tail.

Product class economics diverge sharply. Antibody programmes carry the highest development cost but the largest addressable revenue, while insulins compete on device convenience and supply scale rather than analytical novelty.

By Indication

Sub-Segment	Key Trend
Blood Disorders	Filgrastim and epoetin substitution now near saturation in Europe
Autoimmune & Chronic Inflammatory	Volume growth outpaces value growth as erosion deepens.
Oncology	Checkpoint inhibitor expiries create the decade's largest opportunity.
Diabetes	Insulin adoption widens across public procurement systems.
Growth Deficiency & Others	Somatropin and fertility agents supply niche stability.

Indication mix is shifting from mature inflammatory franchises toward oncology, where the value at risk after 2028 dwarfs anything the sector has absorbed to date.

By End User

Sub-Segment	Key Trend
Hospitals	Infusion-administered products anchor the largest spending base
Specialty Clinics	Reimbursement shifts push oncology care to outpatient settings.
Retail & Homecare	Autoinjector formats expand self-administration
Others	Ambulatory and long-term care channels grow modestly.

Care setting migration is the quiet structural story. Every subcutaneous conversion moves revenue out of hospital pharmacy budgets and into clinic and retail channels.

By Manufacturing Type

Sub-Segment	Key Trend
In-House	Vertically integrated developers protect margin and launch timing.
Contract Manufacturing	Capital-light entrants secure reserved capacity slots.

Ownership of capacity has become a strategic dividing line. Integrated players control launch sequencing; outsourced developers trade that control for lower fixed cost.

By Route of Administration

Sub-Segment	Key Trend
Intravenous	Oncology infusion protocols sustain the current volume base
Sub-Cutaneous	Device conversion releases infusion capacity and wins tenders.

Route is increasingly a competitive variable rather than a clinical constant. Where molecules are equivalent, delivery format decides the award.

Certified Researchers

Enquiry

Customize Report

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

“The Automotive 48V ECU Components Procurement Intelligence Study” was a complex project, but the Market Research Future (MRFR) team handled it with quality, agility, and customer-centricity. They delivered all requested data on time and within the agreed scope. The team, including Shubhendra Anand and Rahul Gotadki, was always readily available to clarify questions and swiftly implement necessary adjustments, driving the project to a successful conclusion within a very demanding timeframe.
I would also like to specifically commend Akshay Agarwal for his responsiveness and support at every stage—from our initial inquiry on May 6th through to final delivery on June 18th. His dedication made the entire process seamless.”

Guilherme Gomes Martins Product Management Director

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”